Welcome to LookChem.com Sign In|Join Free

CAS

  • or

136787-49-0

Post Buying Request

136787-49-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

136787-49-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 136787-49-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,6,7,8 and 7 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 136787-49:
(8*1)+(7*3)+(6*6)+(5*7)+(4*8)+(3*7)+(2*4)+(1*9)=170
170 % 10 = 0
So 136787-49-0 is a valid CAS Registry Number.

136787-49-0Relevant articles and documents

An efficient and general method for the synthesis of α,ω- difunctional reduced polypropionates by Zr-catalyzed asymmetric carboalumination: Synthesis of the scyphostatin side chain

Tan, Ze,Negishi, Ei-Ichi

, p. 2911 - 2914 (2004)

A decrease in the number of linear synthetic steps and an increase in efficiency have been realized in the synthesis of the side chain of scyphostatin. An efficient and selective synthesis of α,ω- difunctional reduced polypropionates from methyl 3-hydroxy-2-methylpropionate through the use of a Zr-catalyzed asymmetric carboalumination has been developed (see scheme, TBS = tert-butyldimethylsilyl).

Carbohydrate/DBU Cocatalyzed Alkene Diboration: Mechanistic Insight Provides Enhanced Catalytic Efficiency and Substrate Scope

Yan, Lu,Meng, Yan,Haeffner, Fredrik,Leon, Robert M.,Crockett, Michael P.,Morken, James P.

supporting information, p. 3663 - 3673 (2018/03/21)

A mechanistic investigation of the carbohydrate/DBU cocatalyzed enantioselective diboration of alkenes is presented. These studies provide an understanding of the origin of stereoselectivity and also reveal a strategy for enhancing reactivity and broadening the substrate scope.

COMPOUNDS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES

-

Page/Page column 28, (2016/05/02)

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 136787-49-0